Back to MW MARSHALL WACE, LLP

STLNSTLN
9 quarters

Position history for MWMARSHALL WACE, LLP's holdings in Starling Oncology, Inc.

Yes. Marshall Wace holds 1,222,498 shares of STLN (Starling Oncology), worth $6.6M, as of its Q2 2026 13F filing. It increased the position from 342,265 shares in Q1 2026. Marshall Wace has held STLN since Q2 2025, across 5 quarterly 13F filings.

Current Value

$6.6M

Current Shares

1.2M

Total Value Change

+$4.1M

Total Shares Change

+970,059

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.2M
+257.2%
$6.6M0.0%$5.43
44
2026-Q1
Increased
342,265
+89.8%
$1.1M0.0%$3.07
39
2025-Q4
Increased
180,300
+616.5%
$641,8680.0%$3.56
39
2025-Q3
Decreased
25,164
-98.3%
$87,8230.0%$3.49
0
2025-Q2
New
1.5M
-
$3M0.0%$2.05
37
2024-Q1
Exited
0
-100.0%
$00.0%$1.58
0
2023-Q4
New
39,282
-
$80,1350.0%$2.04
30
2021-Q4
Exited
0
-100.0%
$00.0%$9.75
0
2021-Q3
New
252,439
-
$2.5M0.0%$9.94
36

Other major holders of STLN: FMR LLC, BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used